

# Mathematical Modeling of Dengue Disease in Infants

Fernando L. P. dos Santos

São Paulo State University/UNESP

WINCB19

International Workshop: Modeling and Calculations for Biomathematics 2019

Essaouira, Marocco

## Joint with

---

- **M.Sc. students:** Felipe A. Camargo and Thiago M. Oliveira;  
*Pos-graduate course, UNESP/Botucatu-SP, Brazil.*
- **Professors:** Claudia P. Ferreira, Diego S. Rodrigues, Paulo F. A. Mancera and Fernando L. P. Santos;  
*Dept. of Biostatistics, UNESP/Botucatu-SP, Brazil.*

# Topics

---

- Introduction
- The main objective
- The mathematical model
- Mathematical analysis
- Sensitivity analysis
- Numerical simulations
- Conclusions
- References

# Introduction

## Dengue fever (DF)

---


- DF: Classical form;
- Transmitted by infected female mosquito of genus *Aedes* (*A. aegypti* and *A. albopictus* );
- 4 distinct serotypes of the Virus (DENV-1 – DEN-4).

Dengue control challenges:

1. No vaccine due to the co-circulation of different serotypes;
2. Unplanned and uncontrolled urbanization (Florentino, et al., 2014, 2019);
3. Mosquito resistance by insecticide (Kuniyoshi &, Santos, 2017),
4. Human mobility (Santos, F.L.P., 2017).

# Spatial distribution of dengue cases

Distribution of dengue, worldwide, 2016



- Aedes mosquitoes are found in **tropical and subtropical climates and urban areas**;
- The Americas region reported more than **2.38 million cases** in 2016.

WHO

# Dengue Hemorrhagic Fever (DHF)

---

- **Severe form:** lethal complication;
- Causes serious **illnesses** and **death** among children and elderly;
- **In infants:** The number of cases has been increasing over the last years.




Figure: Number of hospitalizations for DHF, Brazil, 1998–2007.

# Dengue Hemorrhagic Fever (DHF)

---

Can occur basically in two ways:

1. **Children and adults:** infected with a second serotype of DENV after a primary DENV infection with a different serotype;
2. **in infants:** with primary DENV infection whose mothers have some immunity to DENV.

**Focus:** Study DHF in the context of (2).



# The objectives

---

- To Propose and study a new mathematical model that mimics dengue disease in infants with passive immunity.

# The Mathematical Model


## State variables

---

- $B$ : Antibodies of the infants: **Passive immunity or Primary response of DENV infection by maternal Antibodies.**
- $X$ : DENV–uninfected monocytes;
- $Y$ : DENV–infected monocytes;
- $V$ : free immature DENV;

# Diagram

---



# Dimensional Nonlinear ODE Model

---

$$\left\{ \begin{array}{l} \frac{dB}{dt} = \overbrace{-\alpha B}^{\text{Antibody decay}} \quad \overbrace{-\eta B V}^{\text{DENV neutralization}} \\ \frac{dX}{dt} = \overbrace{A - \mu_1 X}^{\text{Monocytes dynamics}} \quad \overbrace{-\beta V X}^{\text{DENV infection}} \\ \frac{dY}{dt} = \overbrace{-\mu_2 Y}^{\text{Death of monocytes}} + \beta V X \\ \frac{dV}{dt} = \overbrace{kY}^{\text{DENV production}} \quad \overbrace{-\gamma B V}^{\text{Antibody neutralization}} \quad \overbrace{-\delta V}^{\text{Virus decay}} \end{array} \right. \quad (1)$$

# Nondimensionalization

---

Dimensional parameter units:

$$\left\{ \begin{array}{l} [\eta] = \frac{1}{[t]} \cdot \frac{1}{[V]}, \quad [\alpha] = \frac{1}{[t]}, \quad [\beta] = \frac{1}{[t]} \cdot \frac{1}{[V]} \\ [\mu_1] = \frac{1}{[t]}, \quad [A] = \frac{[C]}{[t]}, \quad [\mu_2] = \frac{1}{[t]} \\ [\gamma] = \frac{1}{[t]} \cdot \frac{1}{[B]}, \quad [k] = \frac{1}{[t]} \cdot \frac{[V]}{[C]}, \quad [\delta] = \frac{1}{[t]} \end{array} \right. .$$

# Nondimensionalization

---

Let,

$$\left\{ \begin{array}{l} B^* = \frac{B\gamma}{\alpha} \quad \Rightarrow \quad B = \frac{B^*\alpha}{\gamma}, \\ t^* = t\alpha \quad \Rightarrow \quad t = \frac{t^*}{\alpha}, \\ X^* = \frac{X\mu_1}{A} \quad \Rightarrow \quad X = \frac{X^*A}{\mu_1}, \\ Y^* = \frac{Y\mu_1}{A} \quad \Rightarrow \quad Y = \frac{Y^*A}{\mu_1}, \\ V^* = \frac{V\eta}{\delta} \quad \Rightarrow \quad V = \frac{V^*\delta}{\eta}. \end{array} \right. \quad (2)$$

## Nondimensional Nonlinear ODE Model

---

Substituting (2) in the system (1), we obtain:

$$\begin{cases} \frac{dB}{dt} = -\omega BV - B \\ \frac{dX}{dt} = \rho(1 - X) - \theta XV \\ \frac{dY}{dt} = \theta XV - \varphi Y \\ \frac{dV}{dt} = \epsilon Y - \omega V - BV \end{cases} \quad (3)$$

where,

$$\omega = \frac{\delta}{\alpha}, \quad \rho = \frac{\mu_1}{\alpha}, \quad \theta = \frac{\delta\beta}{\alpha\eta}, \quad \varphi = \frac{\mu_2}{\alpha} \quad \text{e} \quad \epsilon = \frac{\eta kA}{\delta\alpha\mu_1}. \quad (4)$$



# Mathematical Analysis

## Equilibrium points

---

Considering  $\frac{dB}{dt} = \frac{dX}{dt} = \frac{dY}{dt} = \frac{dV}{dt} = 0$  in system (3) and solving the associated homogeneous system, we obtain:

$$\left\{ \begin{array}{l} \bar{B} = 0 \text{ or } \bar{V} = -\frac{1}{\omega} \\ \bar{X} = \frac{\rho}{\rho + \theta \bar{V}} \\ \bar{Y} = \frac{\theta \bar{X} \bar{V}}{\epsilon \bar{Y}} \\ \bar{V} = \frac{\varphi \bar{Y}}{\omega + \bar{B}} \end{array} \right. . \quad (5)$$

## Equilibrium points

---

1. If  $\bar{B} = 0$ ,  $\bar{X} = \frac{\varphi\omega}{\epsilon\theta}$ ,  $\bar{Y} = \frac{\rho}{\theta} \left(1 - \frac{\varphi\omega}{\epsilon\theta}\right)$  and  $\bar{V} = \frac{\rho}{\theta} \left(\frac{\epsilon\theta}{\varphi\omega} - 1\right)$ .

Then,

- **The disease-Free Equilibrium (DFE) point:**  $S_1 = (0, 1, 0, 0)$ .
- **The infection equilibrium point:**

$$S_2 = \left(0, \frac{\varphi\omega}{\theta\epsilon}, \frac{\rho}{\varphi} \left(1 - \frac{\varphi\omega}{\epsilon\theta}\right), \frac{\rho}{\theta} \left(\frac{\epsilon\theta}{\varphi\omega} - 1\right)\right).$$

2. If  $\bar{V} = -\frac{1}{\omega}$ , then

$$S_3 = \left(\frac{\omega(\epsilon\rho\theta - \omega\rho\varphi + \theta\varphi)}{\varphi(\omega\rho - \theta)}, \frac{\rho\omega}{\omega\rho - \theta}, -\frac{\theta\rho}{\varphi(\omega\rho - \theta)}, -\frac{1}{\omega}\right).$$

## Positivity

---

- Let,

$$\mathcal{P}^+ = \left\{ (B, X, Y, V) \in \mathbb{R}^4 : \begin{array}{l} B(0) = B_0 > 0, \\ X(0) = X_0 > 0, Y(0) = Y_0 > 0, V(0) = V_0 > 0 \end{array} \right\}. \quad (6)$$

- All parameters are positive;

Then,

- $S_1 = (0, 1, 0, 0)$  has biological sense;
- $S_2$  has biological sense, if

$$\mathcal{R}_0 = \frac{\epsilon\theta}{\varphi\omega} > 1;$$

- $\mathcal{R}_0$  is the **Basic Reproduction Number**.
- $S_3$  has not biological sense, since  $\bar{V} = -\frac{1}{\omega} < 0$ .

## Numerical behaviour of $S_3$




Figure:  $B_0 = 0.60$ ,  $X_0 = 0.60$ ,  $Y_0 = -0.0002$ ,  $V_0 = -0.0050$ .  $\bar{B} \approx 1.52 \times 10^3$ ,  $\bar{X} \approx 1.09$ ,  $\bar{Y} \approx -2.67 \times 10^4$  and  $\bar{V} \approx -5.99 \times 10^3$ .

## The Linear Stability Analysis

---

The Jacobian matrix  $J$  of nondimensional model (3) evaluated on  $S_1$  and  $S_2$  is:

$$J(S_i) = \begin{pmatrix} -(\omega\bar{V} + 1) & 0 & 0 & -\omega\bar{B} \\ 0 & -(\rho + \theta\bar{V}) & 0 & -\theta\bar{X} \\ 0 & \theta\bar{V} & -\varphi & \theta\bar{X} \\ -\bar{V} & 0 & \epsilon & -(\omega + \bar{B}) \end{pmatrix}. \quad (7)$$

## The Linear Stability Analysis: $S_1$

---

We have

$$J(S_1) = \begin{pmatrix} -1 & 0 & 0 & 0 \\ 0 & -\rho & 0 & -\theta \\ 0 & 0 & -\varphi & \theta \\ 0 & 0 & \epsilon & -\omega \end{pmatrix} \quad (8)$$

In this case, the eigenvalues  $\lambda_i$ ,  $i = 1, \dots, 4$ , obtained from  $\det(J(S_1) - \lambda \mathbf{I}) = 0$  are:

$$\lambda_1 = -1 \text{ e } \lambda_2 = -\rho$$

and

$$\lambda_{3,4} = \frac{1}{2} \left( -(\varphi + \omega) \pm \sqrt{(\varphi + \omega)^2 - 4(\varphi\omega - \epsilon\theta)} \right).$$

## The linear stability Analysis: $S_1$

---

If  $\varphi\omega - \epsilon\theta > 0$ , then

$$\mathcal{R}_0 = \frac{\epsilon\theta}{\varphi\omega} < 1,$$

and thus  $S_1$  is asymptotically stable.



## The linear stability Analysis: $S_2$

---

Considering  $\mathcal{R}_0$ ,  $S_2$  has the form:

$$S_2 = \left( 0, \frac{1}{\mathcal{R}_0}, \frac{\rho}{\varphi} \left( 1 - \frac{1}{\mathcal{R}_0} \right), \frac{\rho}{\theta} (\mathcal{R}_0 - 1) \right).$$

Then,

$$J(S_2) = \begin{pmatrix} -(\omega \bar{V} + 1) & 0 & 0 & 0 \\ 0 & -(\rho + \theta \bar{V}) & 0 & -\theta \bar{X} \\ 0 & \theta \bar{V} & -\varphi & \theta \bar{X} \\ -\bar{V} & 0 & \epsilon & -\omega \end{pmatrix}.$$

## The Linear Stability Analysis: $S_2$

---

Here,

$$\det(J(S_2) - \lambda I) = (\omega \bar{V} + 1 + \lambda) \mathcal{B} = 0,$$

where  $\mathcal{B} = (\rho + \theta \bar{V} + \lambda)(\lambda^2 + \lambda(\varphi + \omega) + \varphi\omega - \epsilon\theta \bar{X}) + \epsilon\theta^2 \bar{X} \bar{V}$ .

1. The one solution is

$$\lambda = -\omega \bar{V} - 1$$

2. and also given by

$$\lambda^3 + a_1 \lambda^2 + a_2 \lambda + a_3 = 0,$$

where

- $a_1 = \varphi + \omega + \rho \mathcal{R}_0$ ;
- $a_2 = \rho \mathcal{R}_0(\varphi + \omega) + \varphi\omega - \frac{\epsilon\theta}{\mathcal{R}_0}$ ;
- $a_3 = \rho \mathcal{R}_0 \varphi\omega - \frac{\epsilon\theta\rho}{\mathcal{R}_0}$ .

## The Linear Stability Analysis: $S_2$

---

- All parameters are positives in  $\mathcal{P}^+$ ;
- If  $\mathcal{R}_0 > 1$ , the *Routh-Hurwitz* conditions for the stability of the linearized system are satisfied in  $\mathcal{P}^+$ , since

$$a_1\varphi + \omega + \rho\mathcal{R}_0 > 0,$$

$$a_3 = \rho\mathcal{R}_0\varphi\omega - \frac{\epsilon\theta\rho}{\mathcal{R}_0} = \rho\varphi\omega(\mathcal{R}_0 - 1) > 0$$

and

$$a_1a_2 - a_3 = \varphi\rho\mathcal{R}_0(\varphi + \omega) + \rho^2\mathcal{R}_0^2(\varphi + \omega) + \omega^2\rho\mathcal{R}_0 + \rho\varphi\omega > 0.$$

Thus,

$S_2$  is asymptotically stable and  $S_1$  is unstable.

# Sensitivity Analysis

# Sensitivity Analysis

---

Linear correlation for  $\epsilon$  and  $\theta$  with  $\mathcal{R}_0 = \frac{\epsilon\theta}{\varphi\omega}$ .




Figure: PRCC = 0.514582 and PRCC = 0.989135, respectively.

*Partial Rank Correlation Coefficient (PRCC) method.*

# Sensitivity Analysis

---

Linear correlation for  $\omega$  and  $\varphi$  with  $\mathcal{R}_0 = \frac{\epsilon\theta}{\varphi\omega}$ .




Figure: PRCC = -0.668597 and PRCC = -0.883255, respectively.

# Sensitivity Analysis

---




Figure: Partial correlation coefficient for the  $\epsilon$ ,  $\theta$ ,  $\omega$ ,  $\varphi$  and dummy with  $\mathcal{R}_0$ .

# Numerical Simulations



# Numerical Simulations


---

Table: Parameters for the simulations.

Parameter	Values ( $\mathcal{R}_0 < 1$ )	Values ( $\mathcal{R}_0 > 1$ )
$\rho$	$3.33 \times 10^{-1}$	$3.33 \times 10^{-1}$
$\epsilon$	$3.82 \times 10^4$	$3.82 \times 10^4$
$\varphi$	$1.16 \times 10^2$	$1.16 \times 10^2$
$\theta$	$4.74 \times 10^{-1}$	$4.74 \times 10$
$\omega$	$1.66 \times 10^2$	$1.66 \times 10^2$

- Age of the infant: 4 - 6 months (Castanha *et al.*, 2016);
- $t_0 = 0$  : initial time of Dengue infection in the infants;
- Time-step  $\Delta t = 10^{-4}$  for the *Runge-Kutta* fourth-order method;
- $\mathcal{R}_0 = \epsilon\theta/\varphi\omega$ .


## Numerical Simulations: $\mathcal{R}_0 < 1$



**Figure:** Convergency of the solution  $(B, X, Y, V)$  to the free-disease equilibrium point,  $S_1 = (0, 1, 0, 0)$ .


## Numerical Simulations: $\mathcal{R}_0 > 1$

---




**Figure:** Convergency of the solution  $(B, X, Y, V)$  to the endemic-disease equilibrium point,  $S_2$ ;  $\bar{B} = 0$ .

## Numerical Simulations: Scenario $\mathcal{R}_0 > 1$




(a)




(b)

**Figure:** Population dynamics of the monocytes uninfected cells along the time  $t$ . (a)  $t \in [0, 0.1]$ ; (b)  $t \in [0.1, 5]$ . Initial conditions:  $B_0 = 0.60$ ,  $Y_0 = 0.00$ ,  $V_0 = 0.50$ .  $\bar{X} \approx 1.07 \times 10^{-1}$ .

## Numerical Simulations: Scenario $\mathcal{R}_0 > 1$




(a)




(b)

**Figure:** Population dynamics of the monocytes infected cells along the time  $t$ . (a)  $t \in [0, 0.1]$ ; (b)  $t \in [0.1, 5]$ . Initial conditions:  $B_0 = 0.60$ ,  $X_0 = 0.60$ ,  $V_0 = 0.50$ ;  $\bar{Y} \simeq 2.5 \times 10^{-3}$ .

## Numerical Simulations: Scenario $\mathcal{R}_0 > 1$



(a)



(b)

**Figure:** Population dynamics of the virus along the time  $t$ . (a)  $t \in [0, 0.1]$   
e (b)  $t \in [0.1, 5)$ . Initial conditions:  $B_0 = 0.60$ ,  $X_0 = 0.60$ ,  $Y_0 = 0.00$ ;  
 $V^* \simeq 5.84 \times 10^{-1}$ .

# Conclusions

## Conclusions

---

1. The numerical results of the computational simulations are in agreement with the mathematical analysis performed;
2. The sensitivity analysis showed that the parameter of the infection  $\theta$  has a strong and positively correlation to the  $\mathcal{R}_0$ ;
3. From the numerical results, the peaks were visualized in the dynamics of  $Y$  and  $V$ ; (Gómez & Yang, 2018) classified these peaks as DHF.
4. From our hypothesis of passive immunity meaning the primary response mediated by maternal antibodies, we can conclude that this peak mean DHF in infants.



## Improvements on the Model

---

Neutralization and Enhancement as a function of antibodies concentration:


$$N_j(B) = \eta_j + s_j \frac{B^n}{r_j^n + B^n} \mathbb{1}_{B > B_0}, \quad \text{with } j = 1, 2,$$

and

$$E(B) = q \left( e^{-\frac{(B-\epsilon)^2}{2\sigma_1}} \mathbb{1}_{B \leq \epsilon} + e^{-\frac{(B-\epsilon)^2}{2\sigma_2}} \mathbb{1}_{B > \epsilon} \right).$$

# Antibodies Neutralization and Enhancement functions





---



M. Adimy; P. Mancera; D. Rodrigues; F. dos Santos; C. Ferreira. "Maternal passive immunity and dengue hemorrhagic fever in infants", submitted to Bulletin of Mathematical Biology, 2019.






## References

---

-  C. M. Gómez and H. M. Yang. A simple mathematical model to describe antibody-dependent enhancement in heterologous secondary infection in dengue. *Mathematical Medicine and Biology : A Journal of the IMA*. p.1-28, 2018.
-  Florentino, H. O.; Cantane, D. R.; Santos, F. L. P.; Reis, C. A.; Pato, M. M. G. V.; Jones, D.; Oliveira, R. A.; Lyra, L. G. GENETIC ALGORITHM FOR OPTIMIZATION OF THE *Aedes aegypti* CONTROL STRATEGIES. *PESQUISA OPERACIONAL (ONLINE)*. , v.38, p.389 - 411, 2018.
-  Kuniyoshi, M. L. G. ; Santos,, F. L. P. Mathematical modelling of vector-borne diseases and insecticide resistance evolution. *J. of VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES*, v. 23, p. 23-34, 2017.
-  Santos, F. L. P. Patches Approach to Investigate the Populational Dynamics in Dengue. *TEMA. Trends in Applied and Computational Mathematics*, v. 18, p. 3-14, 2017.




## References

---

-  Florentino, H. O.; Cantane, D. R.; Santos, F. L. P.; Bannwart, B. F. Multiobjective Genetic Algorithm applied to dengue control. *Mathematical Biosciences*, v. 258, p. 77-84, 2014.
-  A. Aggarwal, J. Chandra, S. Aneja *et al.*, *An epidemic of dengue hemorrhagic fever and dengue shock syndrome in children in Delhi*. *Indian Pediatr* 35: 727–732, 1998.
-  S. Bhatt, P. W. Gething, O. J. Brady *et al.*, *The global distribution and burden of dengue*. *Nature* 496: 504–507, 2013.
-  R. Z. Capeding, J. D. Brion, M. M. Caponpon *et al.*, *The incidence, characteristics, and presentation of dengue virus infections during infancy*. *Am J Trop Med Hyg* 82: 330–336, 2010.
-  G. Carles, H. Peiffer and A. Talarmin, *Effects of dengue fever during pregnancy in French Guiana*. *Clin Infect Dis* 3: 637–640, 1999.

## References

---

-  P. M. S. Castanha, C. Braga, M. T. Cordeiro *et al.*, *Placental transfer of dengue virus (DENV) – Specific antibodies and kinetics of DENV infection–enhancing activity in brazilian infants.* J Infect Dis 214: 265–272, 2016.
-  G. A. Funk, A. D. Barbour, H. Hengartner and U. Kalinke, *Mathematical model of a virus–neutralizing immunoglobulin response.* J Theor Biol 198: 41–52, 1998.
-  M. G. Guzman, M. Alvarez and S. B. Halstead, *Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.* Arch Virol 158: 1445–1459, 2013.

## References

---

-  S. B. Halstead, N. T. Lan, T. T. Myint *et al.*, *Dengue hemorrhagic fever in infants: research opportunities ignored*. *Emerg Infect Dis* 8:1474–1479, 2002.
-  A. Jain and U. C. Chaturvedi, *Dengue in infants: an overview*. *FEMS Immunol Med Microbiol* 59, 119–130, 2010.
-  R. Nikin-Beers and S. M. Ciupe, *The role of antibody in enhancing dengue virus infection*. *Math Bios* 263: 83–92, 2015.
-  P. Palmeira, C. Quinello, A. L. Silveira-Lessa *et al.*, *IgG placental transfer in healthy and pathological pregnancies*. *Clin Dev Immunol* 2012: 1–13, 2012.

**Acknowledgements:** Grant 2018/03116-3, São Paulo Research Foundation (FAPESP).

**Thank You!**